An announcement from Johnson & Johnson ( (JNJ) ) is now available.
D. Adamczyk announced his intention to retire from Johnson & Johnson‘s Board of Directors effective May 31, 2025, to join Goldman Sachs as a Partner, citing personal reasons unrelated to any disagreements with the company. At the 2025 Annual Meeting of Shareholders held on April 24, 2025, all 11 Director nominees were elected, executive compensation policies were approved, and PricewaterhouseCoopers LLP was ratified as the independent auditor for 2025. However, proposals on shareholder voting for excessive golden parachutes and a human rights impact assessment were not approved.
Spark’s Take on JNJ Stock
According to Spark, TipRanks’ AI Analyst, JNJ is a Outperform.
Johnson & Johnson’s overall stock score reflects its strong financial performance and robust operational growth, particularly in innovative medicine and MedTech segments. The fair valuation and attractive dividend yield add to its appeal. However, technical indicators suggest cautious optimism due to mixed signals. Challenges such as the STELARA sales decline and legal proceedings pose risks that could impact future performance.
To see Spark’s full report on JNJ stock, click here.
More about Johnson & Johnson
YTD Price Performance: 8.28%
Average Trading Volume: 9,771,880
Technical Sentiment Signal: Strong Sell
Current Market Cap: $374.4B
Learn more about JNJ stock on TipRanks’ Stock Analysis page.